REGN vs SEPN: fair value comparison
Regeneron Pharmaceuticals, Inc. and Septerna, Inc. · Updated 2026-10-19
SEPN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, REGN currently ranks higher by quality score.
| REGN | SEPN | |
|---|---|---|
| Verdict | Fairly valued | No estimate yet |
| Last price | $746.54 | $36.35 |
| 12-month range | $575.69–$852.03 | $18.10–$48.19 |
| Rank by discount to fair value | #46 of 108 Healthcare | — |
| Rank by quality score | #19 of 301 Healthcare | #21 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Fairly Valued | — |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: REGN fair value analysis · SEPN fair value analysis